They demonstrated that the CRC models recapitulate many of the genetic and transcriptomic features of the donors, and that there is a link between molecular profiles and drug sensitivity patterns, including a signature outperforming RAS/RAF mutations that predicts sensitivity to EGFR inhibitors. This evidence concerns the gene EGFR and colorectal carcinoma.